Seagen (SGEN) Gets Early FDA Nod for Tivdak in Cervical Cancer (Revised)

The FDA grants accelerated nod to Seagen (SGEN) and Genmab’s Tivdak for treating adult patients with recurrent/metastatic cervical cancer with disease…

Leave a Reply

Your email address will not be published. Required fields are marked *